Brought to you by 
Bennu to develop cysteamine under IP license from UCSD
15 Feb 2017
Executive Summary
Bennu Pharmaceuticals, the drug development division of Raptor (targets both large pharmaceutical markets and orphan indications), received exclusive worldwide rights to the University of California, San Diego's IP covering the treatment of nonalcoholic steatohepatitis (NASH) with cysteamine and delayed-release cysteamine.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bennu to develop cysteamine under IP license from UCSD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice